Pasithea Therapeutics (KTTA)Cable Car Capital, LP added to its stake +706K shares

1.21M

Shares reported · +706K vs prior quarter

0.38%

Disclosed portfolio weight

$895K

Reported value

Holdings as of

Mar 31, 2026

Filed

May 15, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. May 1, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.”

What came next

1. Jun 17, 2026Insider · Their first buy on record10% owner purchased ~$53K of KTTA shares in the open market
2. Aug 20, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously reported, on February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for the prior 30 consecutive business days, the Company was not in compliance…”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Pasithea Therapeutics

For Pasithea Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.

How this filing works

• SEC Form 13F

Other disclosures at Pasithea Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Jun 22, 2026
• SEC Form 4Dec 1, 2025
• SEC Form 4Dec 1, 2025
• SEC Form 4Dec 1, 2025
• SEC Form 4May 15, 2025

Everything OQRO holds on this company is on its KTTA page.